TScan Therapeutics’ (TCRX) “Outperform” Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a report published on Tuesday morning,RTT News reports. The firm currently has a $7.00 target price on the stock, down from their prior target price of $10.00.

Several other brokerages also recently issued reports on TCRX. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a research note on Tuesday, November 12th.

TScan Therapeutics Trading Down 1.9 %

Shares of NASDAQ:TCRX opened at $3.02 on Tuesday. The business’s 50-day moving average is $4.87 and its 200 day moving average is $5.91. The firm has a market capitalization of $161.18 million, a P/E ratio of -2.85 and a beta of 0.79. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. TScan Therapeutics has a 1 year low of $2.60 and a 1 year high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The firm had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.86 million. On average, research analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Insider Buying and Selling at TScan Therapeutics

In other TScan Therapeutics news, Director Barbara Klencke purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The shares were acquired at an average cost of $5.29 per share, for a total transaction of $26,450.00. Following the completion of the acquisition, the director now owns 45,000 shares of the company’s stock, valued at $238,050. The trade was a 12.50 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.76% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Stifel Financial Corp grew its holdings in TScan Therapeutics by 3.9% in the 3rd quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock worth $494,000 after acquiring an additional 3,733 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in TScan Therapeutics in the second quarter worth approximately $70,000. MetLife Investment Management LLC lifted its position in shares of TScan Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock valued at $116,000 after acquiring an additional 13,164 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in TScan Therapeutics during the 2nd quarter valued at approximately $90,000. Finally, SG Americas Securities LLC bought a new position in shares of TScan Therapeutics in the 3rd quarter valued at about $78,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.